Biomarin Pharmaceutical Inc (BMRN)

77.66 +1.31  +1.72% NASDAQ Mar 5, 16:59 USD
View Full Chart
Price Chart
View All BMRN News

News

View All Events

Events

Date Type Description
04/30/2021 Earnings Biomarin Pharmaceutical Inc First Quarter Earnings Results for 2021
04/30/2021 Misc Biomarin Pharmaceutical Inc First Quarter Earnings Conference Call for 2021
02/25/2021 Earnings Biomarin Pharmaceutical Inc Fourth Quarter Earnings Result for 2020
02/25/2021 16:30 EST Misc Biomarin Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Biomarin Pharmaceutical Inc Third Quarter Earnings Result for 2020
11/05/2020 16:30 EST Misc Biomarin Pharmaceutical Inc Third Quarter Earnings Conference Call for 2020
08/04/2020 16:30 EDT Misc Biomarin Pharmaceutical Inc Second Quarter Earnings Conference Call for 2020
08/04/2020 Earnings Biomarin Pharmaceutical Inc Second Quarter Earnings Result for 2020
05/27/2020 09:00 PDT Misc Biomarin Pharmaceutical Inc Annual General Meeting for 2019
04/30/2020 16:30 EDT Misc Biomarin Pharmaceutical Inc First Quarter Earnings Conference Call for 2020
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.bmrn.com
  • Investor Relations URL: http://investors.bmrn.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Blend
  • Next Earnings Release: Apr. 30, 2021
  • Last Earnings Release: Feb. 25, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Top Fund Holders

Symbol Name Weighting
PBE Invesco Dynamic Biotech & Genome ETF 4.91%
FBT First Trust NYSE Arca Biotech ETF 3.33%
BBH VanEck Vectors Biotech ETF 3.00%
VHCOX Vanguard Capital Opportunity Inv 2.38%
HQL Tekla Life Sciences Investors 2.06%
POGRX PRIMECAP Odyssey Growth 1.74%
CMGRX Columbia Mid Cap Growth R 1.68%
POAGX PRIMECAP Odyssey Aggressive Growth 1.60%
HQH Tekla Healthcare Investors 1.40%
JFNSX Janus Henderson Global Life Sciences S 1.32%
IBB iShares Nasdaq Biotechnology ETF 1.17%
CAFFX American Funds AMCAP 529F1 1.11%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.